Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.
Kim RandJuan Manuel Ramos-GoñiBülent AkmazLaia Solé-FeuJosé Carlos Armario-HitaPublished in: Dermatology and therapy (2024)